(Total Views: 630)
Posted On: 04/23/2021 8:30:10 AM
Post# of 148899
https://www.cytodyn.com/newsroom/press-releas...-financing
I would suggest that investors, especially newbies, read this part of the PR carefully:
"The HIV BLA request for rolling review in Q3 2021 with remaining portions later in the year is on schedule. We are leveraging our long-term HIV extension patients to provide insight into the benefit of Vyrologix. The top 10 cancers associated with CCR5 include: urothelial cancer, breast cancer, lung squamous cell carcinoma, colorectal cancer, lung adenocarcinoma, pancreatic cancer, head and neck cancer, TNBC, and sarcoma. We have modified our basket trial for oncology and have a new strategy looking at cancers from a basic research level to clinical with preliminary results by Q4 of this year.”
This is your company. It is not merely another "jump on COVID bandwagon microcap". Cytodyn is a multi-faceted biotechnology company with real potential to mitigate a number of severe conditions. This is why so many of us invested in the first place.
I would suggest that investors, especially newbies, read this part of the PR carefully:
"The HIV BLA request for rolling review in Q3 2021 with remaining portions later in the year is on schedule. We are leveraging our long-term HIV extension patients to provide insight into the benefit of Vyrologix. The top 10 cancers associated with CCR5 include: urothelial cancer, breast cancer, lung squamous cell carcinoma, colorectal cancer, lung adenocarcinoma, pancreatic cancer, head and neck cancer, TNBC, and sarcoma. We have modified our basket trial for oncology and have a new strategy looking at cancers from a basic research level to clinical with preliminary results by Q4 of this year.”
This is your company. It is not merely another "jump on COVID bandwagon microcap". Cytodyn is a multi-faceted biotechnology company with real potential to mitigate a number of severe conditions. This is why so many of us invested in the first place.
(9)
(1)Scroll down for more posts ▼
